Practice 5
Appropriate to offer biopsy of accessible metastases to assess biological markers (such as oestrogen and progesterone receptors and HER2 status), and to offer germline genetic testing for BRCA1/2, if the result is likely to lead to a change in the management of patients with metastatic breast cancer.
Context
Appropriate to offer biopsy of accessible metastases to assess biological markers (such as oestrogen and progesterone receptors and HER2 status), and to offer germline genetic testing for BRCA1/2, if the result is likely to lead to a change in the management of patients with metastatic breast cancer.
Value to patients
Appropriate to offer biopsy of accessible metastases to assess biological markers (such as oestrogen and progesterone receptors and HER2 status), and to offer germline genetic testing for BRCA1/2, if the result is likely to lead to a change in the management of patients with metastatic breast cancer.
Supporting evidence
Appropriate to offer biopsy of accessible metastases to assess biological markers (such as oestrogen and progesterone receptors and HER2 status), and to offer germline genetic testing for BRCA1/2, if the result is likely to lead to a change in the management of patients with metastatic breast cancer.